## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Merck Sharp & Dohme Limited

Serial No.:

To Be Assigned

Case No.: T1600YP

US Nat'l Filing Date:

April 27, 2005

Int'l Appl'n No.

PCT/GB03/004707

Int'l Filing Date:

29 October 2003

For:

SULFONAMIDES, SULFAMATES AND SULFAMIDES AS

**GAMMA-SECRETASE INHIBITORS** 

MAIL STOP PCT Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT \_ EXPRESS MAIL NO. \_

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450

MAILED BY A OR

DATE



Int'l Appl'n 1

PCT/GB03/004707

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References A & B were listed in the International Search Report during the International phase of this application.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the non-U.S. patent documents that are cited on the attached form PTO-1449 are enclosed herewith.

All the references cited on the attached form were cited in the International Search Report for this application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

ohn C. Todaro, Reg. No. 36,036

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0125

Date: April 27, 2005

JC20 Rec'd PCT/P	roved for use through Information Di alk Offic (U.S.DE	gh 7/31/200 s <b>A</b> s Pa	6. OMB ten av T of d	0651-003 Applicant IN ERCE
COMPLETI	IM WA	15	<u>Zz</u>	10

	_		UULUTIC	The state of the s	
Substitute for form 1449A/PTO INFORMATION DISCLARE		COMPLET 1 1 1 1 5 3 3 1 5 1			
		Application Number	PCT/GB03/		
STATEMENT BY APPLICANT		Filing Date	April 27, 2005		
		First Named Inventor	Andrew Madin et al.		
		,	Group Art Unit	To Be Assigned	
(use as many sneets as necessary)		Examiner Name	To Be Assigned		
1	of	1	Attorney Docket Number	T1600YP	
	NFORMATION TATEMENT BY	NFORMATION DIS  TATEMENT BY AP  (use as many sheets as n	TATEMENT BY APPLICANT  (use as many sheets as necessary)	TATEMENT BY APPLICANT  (use as many sheets as necessary)  Application Number  Filing Date  First Named Inventor  Group Art Unit  Examiner Name	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
			-		

	FOREIGN PATENT DOCUMENTS						
	-	Foreign Patent Document			Date of Publication of		
	Cite No.	Office	Number	Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
	Α		WO 02/36555	P	PCT	Merck Sharp & Dohme Limited	05/10/2002
	В		WO 01/70677	P	PCT	Merck Sharp & Dohme Limited and	
						Merck Frosst Canada & Co.	09/27/2001
						·	
			-				

Examiner	Date
Signature	Considered